US · Healthcare · Medical Devices
EPS came in at 0.08 against a street estimate of 0.12 — a miss of 33.3%.
Analysts rate Artivion Inc a strong buy (6 buy, 0 hold, 0 sell out of 6) with an average price target of $42.00.
| Fund | Stake |
|---|---|
| BlackRock Inc | 13.34% |
| FMR Inc | 5.32% |
| Delaware Management Holdings Inc | 5.06% |
| Morgan Stanley - Brokerage Accounts | 4.67% |
| Vanguard Capital Management, LLC | 4.02% |
| State Street Corp | 3.47% |
| Perceptive Advisors LLC | 3.37% |
| Conestoga Capital Advisors, LLC | 3.34% |
| Document | Date |
|---|---|
| Reg FD disclosure · Q2 2026 | 2026-05-18 |
| Shareholder vote results · Q2 2026 | 2026-05-15 |
| Quarterly report · Q1 2026 | 2026-05-08 |
| Results announced · Q2 2026 | 2026-05-07 |
| Proxy statement · Q2 2026 | 2026-04-01 |
| Annual report FY2025 | 2026-02-18 |
| Results announced · Q1 2026 | 2026-02-12 |
| Quarterly report · Q3 2025 | 2025-11-07 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Artivion Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.